InflaRx's INF904 Will Initially Target Chronic Spontaneous Urticaria And Hidradenitis Suppurativa, With Initiation Of A Phase 2a PK Dose-ranging Study Expected By The End Of 2024, With Data Availability Anticipated In 2025

3/21/24 7:15:06 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IFRX alert in real time by email

Get the next $IFRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IFRX

Date	Price Target	Rating	Analyst
4/5/2023	$8.00	Neutral → Buy	Guggenheim
2/28/2022		Buy → Neutral	Guggenheim
11/8/2021	$14.00 → $15.00	Strong Buy	Raymond James
10/28/2021	$14.00	Outperform → Strong Buy	Raymond James
8/6/2021	$11.00 → $10.00	Outperform	Raymond James
8/6/2021	$2.80 → $2.50	Underperform	Credit Suisse

More analyst ratings

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of GOHIBIC (vilobelimab), under exceptional circumstances for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of standard of care and receiving invasive mechanical ventilation (IMV) (with or without extracorporeal membrane oxygen
11/15/24 7:51:46 AM ET
$IFRX
Biotechnology: Pharmaceutical Preparations
Health Care
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable interim analysis, with guidance for trial size adaptation or futility expected by the end of 2Q 2025InflaRx pipeline highlighted at multiple medical congresses, including vilobelimab in COVID-19 and hidradenitis suppurativa (HS) and INF904Phase 2a trial for INF904 expected to initiate by year-end 2024, with first data readout expected in summer 2025European Committee for Medicinal Products for Human Use (CHMP) review of vilobelimab continues, with discussions ongoing and a CHMP opinion anticipated around mid-NovemberCash, cash equivalents and marketable securities of €62.0 million, e
11/8/24 7:30:00 AM ET
$IFRX
Biotechnology: Pharmaceutical Preparations
Health Care
InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference
JENA, Germany, Oct. 31, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its third quarter 2024 financial and operating results on Friday, November 8, 2024, before the market opens. No conference call is planned. In addition, InflaRx will participate in the following investor event: Guggenheim Securities Inaugural Healthcare Innovation ConferenceNovember 11-13, 2024, Boston, MAFireside chat: November 11th, 11:00 am ET A link to register for the fireside chat live stream and its replay is available here. The company will also participa
10/31/24 7:30:00 AM ET
$IFRX
Biotechnology: Pharmaceutical Preparations
Health Care

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference
JENA, Germany, Oct. 31, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its third quarter 2024 financial and operating results on Friday, November 8, 2024, before the market opens. No conference call is planned. In addition, InflaRx will participate in the following investor event: Guggenheim Securities Inaugural Healthcare Innovation ConferenceNovember 11-13, 2024, Boston, MAFireside chat: November 11th, 11:00 am ET A link to register for the fireside chat live stream and its replay is available here. The company will also participa
10/31/24 7:30:00 AM ET
$IFRX
Biotechnology: Pharmaceutical Preparations
Health Care
InflaRx to Report Second Quarter 2024 Results on August 8, 2024
JENA, Germany, Aug. 01, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its second quarter 2024 financial and operating results on August 8, 2024, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory me
8/1/24 7:30:00 AM ET
$IFRX
Biotechnology: Pharmaceutical Preparations
Health Care
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
JENA, Germany, April 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2024 financial and operating results on May 8, 2024, before the market opens. No conference call is planned for the first quarter 2024 results. InflaRx also announced it will host a virtual research and development event on June 5, 2024. Guided by internationally renowned thought leaders, this event will focus on the planned development of our new oral small molecule C5aR inhibitor, INF904, and the role of C5aR in chronic spontaneous urticaria (CSU) and h
4/30/24 7:30:00 AM ET
$IFRX
Biotechnology: Pharmaceutical Preparations
Health Care

InflaRx's INF904 Will Initially Target Chronic Spontaneous Urticaria And Hidradenitis Suppurativa, With Initiation Of A Phase 2a PK Dose-ranging Study Expected By The End Of 2024, With Data Availability Anticipated In 2025

Chat with this insight

Recent Analyst Ratings for
$IFRX

$IFRX
Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target

InflaRx shares are trading higher after the company announced GOHIBIC was selected by BARDA for a Phase 2 study on acute respiratory distress syndrome.

InflaRx Announces GOHIBIC (Vilobelimab) Selected By BARDA For Phase 2 Study On Acute Respiratory Distress Syndrome; One Of Three Investigational Therapies Chosen By U.S. Department Of Health And Human Services

$IFRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by InflaRx N.V.

SEC Form SC 13G filed by InflaRx N.V.

SEC Form SC 13G/A filed by InflaRx N.V. (Amendment)

$IFRX
Leadership Updates

Live Leadership Updates

InflaRx Appoints Jan Medina as Head of Investor Relations

InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

$IFRX
SEC Filings

SEC Form 6-K filed by InflaRx N.V.

SEC Form 6-K filed by InflaRx N.V.

SEC Form 6-K filed by InflaRx N.V.

$IFRX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

InflaRx upgraded by Guggenheim with a new price target

InflaRx downgraded by Guggenheim

Raymond James reiterated coverage on InflaRx with a new price target

$IFRX
Press Releases

Fastest customizable press release news feed in the world

$IFRX
Financials

Live finance-specific insights

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024

InflaRx's INF904 Will Initially Target Chronic Spontaneous Urticaria And Hidradenitis Suppurativa, With Initiation Of A Phase 2a PK Dose-ranging Study Expected By The End Of 2024, With Data Availability Anticipated In 2025

Chat with this insight

Recent Analyst Ratings for $IFRX

$IFRX Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target

InflaRx shares are trading higher after the company announced GOHIBIC was selected by BARDA for a Phase 2 study on acute respiratory distress syndrome.

InflaRx Announces GOHIBIC (Vilobelimab) Selected By BARDA For Phase 2 Study On Acute Respiratory Distress Syndrome; One Of Three Investigational Therapies Chosen By U.S. Department Of Health And Human Services

$IFRX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by InflaRx N.V.

SEC Form SC 13G filed by InflaRx N.V.

SEC Form SC 13G/A filed by InflaRx N.V. (Amendment)

$IFRX Leadership Updates

Live Leadership Updates

InflaRx Appoints Jan Medina as Head of Investor Relations

InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

$IFRX SEC Filings

SEC Form 6-K filed by InflaRx N.V.

SEC Form 6-K filed by InflaRx N.V.

SEC Form 6-K filed by InflaRx N.V.

$IFRX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

InflaRx upgraded by Guggenheim with a new price target

InflaRx downgraded by Guggenheim

Raymond James reiterated coverage on InflaRx with a new price target

$IFRX Press Releases

Fastest customizable press release news feed in the world

$IFRX Financials

Live finance-specific insights

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024

Recent Analyst Ratings for
$IFRX

$IFRX
Market Insights

$IFRX
Large Ownership Changes

$IFRX
Leadership Updates

$IFRX
SEC Filings

$IFRX
Analyst Ratings

$IFRX
Press Releases

$IFRX
Financials